Metastatic Renal Cell Cancer
28
1
4
19
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
11 trials with published results (39%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
10.7%
3 terminated out of 28 trials
86.4%
-0.1% vs benchmark
4%
1 trials in Phase 3/4
58%
11 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (28)
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer
Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.